Skip to main content
SanofiPartnership

Press Release: Q3 2026: double-digit growth in sales and business EPS FY 2026: guidance upgraded

Source: Autobound Signal API · 81 signals tracked for Sanofi · updated

Get Sanofi's live signals in Claude or ChatGPT, or by API

AskWhat changed at Sanofi this week? Use Autobound signals for sanofi.com.

What happened

Sanofi entered into a partnership with Cheplapharm covering a number of legacy medicines to simplify its portfolio.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Q3 2026: double-digit growth in sales and business EPS FY 2026: guidance upgraded October 30, 2026 Q3 sales growth of 14.3% at CER 1 and business earnings per share (EPS) 2 of €3.55 Pipeline update Guidance upgraded Belén Garijo, Chief Executive Officer: "Sanofi achieved another strong quarter with double-digit sales growth of 14.3%, mainly driven by our new medicines and Dupixent. Business EPS increased by 19.6%, driven by cost discipline. The pipeline milestones included two regulatory approvals, one regulatory submission, and two additional regulatory designations. Our strong commercial and financial momentum to date leads us to raise our 2026 guidance: sales growth is now expected at a low-teens percentage and business EPS growth at a mid-teens percentage, underscoring our sustainable, profitable growth. In the third quarter, we accelerated Sanofi's transformation by expanding our long-standing alliance with Regeneron, which opens up further opportunities in immunology. We also continued to simplify our portfolio through a partnership with Cheplapharm covering a number of legacy medicines 4 . We are confident about our ability to pursue our strong commercial and financial performance in the short and medium term. The whole organisation is focused on managing Sanofi's post-Dupixent trajectory over the next decade. Our priority is to protect earnings through Dupixent's...

Keep reading with a free account

The rest of this article, and every signal for Sanofi, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Partnership

What this signalsA new partnership often opens integration and co-selling work.

Companies

  • CheplapharmPartnercheplapharm.com

The full record

From the Signal API record

Extraction

Confidence
90%
Detected
Oct 30, 2026
signal_type
news
signal_subtype
partners_with

Use this data

Get every partnership signal for Sanofi and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Sanofi this week?”

  2. Send it to your own tools

    The Signal API returns partnership signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/3e373cf3-cd56-61c0-e19d-5f7180bfb180 returns this record as JSON. POST /v1/companies/enrich returns every signal for sanofi.com.

{
  "signal_id": "3e373cf3-cd56-61c0-e19d-5f7180bfb180",
  "signal_type": "news",
  "signal_subtype": "partners_with",
  "detected_at": "2026-10-30T06:30:00+00:00",
  "company": {
    "name": "Sanofi",
    "domain": "sanofi.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/10/30/3392028/0/en/press-release-q3-2026-double-digit-growth-in-sales-and-business-eps-fy-2026-guidance-upgraded.html",
    "title": "Press Release: Q3 2026: double-digit growth in sales and business EPS FY 2026: guidance upgraded",
    "excerpt": "Q3 2026: double-digit growth in sales and business EPS FY 2026: guidance upgraded October 30, 2026 Q3 sales growth of 14.3% at CER 1 and business earnings per share (EPS) 2 of €3.55 Pipeline update Guidance upgraded Belén Garijo, Chief Executive Officer: “Sanofi achieved another strong quarter with double-digit sales growth of 14.3%, mainly driven by our new medicines and Dupixent. Business EPS increased by 19.6%, driven by cost discipline. The pipeline milestones included two regulatory approvals, one regulatory submission, and two additional regulatory designations. Our strong commercial and financial momentum to date leads us to raise our 2026 guidance: sales growth is now expected at a low-teens percentage and business EPS growth at a mid-teens percentage, underscoring our sustainable, profitable growth. In the third quarter, we accelerated Sanofi’s transformation by expanding our long-standing alliance with Regeneron, which opens up further opportunities in immunology. We also continued to simplify our portfolio through a partnership with Cheplapharm covering a number of legacy medicines 4 . We are confident about our ability to pursue our strong commercial and financial performance in the short and medium term. The whole organisation is focused on managing Sanofi’s post-Dupixent trajectory over the next decade. Our priority is to protect earnings through Dupixent’s loss...",
    "summary": "Sanofi entered into a partnership with Cheplapharm covering a number of legacy medicines to simplify its portfolio.",
    "planning": false,
    "image_url": "https://ml-eu.globenewswire.com/Resource/Download/06da731a-67a1-4258-939f-6ef0531ee3bf",
    "confidence": 0.9,
    "published_at": "2026-10-30T06:30:00Z",
    "article_sentence": "We also continued to simplify our portfolio through a partnership with Cheplapharm covering a number of legacy medicines 4 .",
    "related_company_name": "Cheplapharm",
    "related_company_domain": "cheplapharm.com"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.